Recent Updates
Recently added Catalysts

MiniMed Group, Inc.

MMEDFDA catalysts, PDUFA dates & pipeline intelligence
$16.26
▼ -0.73 · -4.3%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MMED financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
6.97 M
Value Traded
113.90 M
Short % Float
3.51%
Days to Cover
1.0
-9.03%Week
-7.03%1 Month
-19.43%3 Month
+38.74%6 Month
-35.84%5 Year
-35.84%All Time

Cash Data

Unlock MMED cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.57 B
EPS (TTM)
-1.12
P/E Ratio
-
Ent. Value
4.37 B
Total Shares
281.35 M
Float Shares
279.80 M
Insiders
0.55%
Institutions
29.17%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MMED catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MMED Catalyst Timeline

Dated clinical, regulatory and corporate events for MiniMed Group, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for MiniMed Group, Inc.

33Total events
6Upcoming
8Tier-1 (high impact)
2026 to 2027Coverage

Upcoming catalysts 2

T2Quarterly Update
Subscribe to view catalyst details
T2Management Change
Subscribe to view catalyst details

Event history 23

▲Product LaunchPost-Market
MiniMed begins commercial shipments of MiniMed Flex system across Europe
insulin-requiring diabetes (type 1 and type 2)source ↗
▲FDA ApprovalFDA Decision
FDA clears MiniMed Fit tubeless insulin pump for ages 7+ with Type 1 and Type 2 diabetes
Type 1 and Type 2 diabetessource ↗
●Management ChangeCorporate
David Segal, M.D. appointed Chief Medical Officer of MiniMed
▲AcquiredCorporate
MiniMed completes separation from Medtronic and becomes fully independent
●Management ChangeCorporate
Amy Bricker and Tim L. Main join MiniMed Board of Directors
▲Stock ListingCorporate
MiniMed completes separation from Medtronic and begins trading as independent company on Nasdaq (MMED)
▲Corporate ApprovalCorporate
Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed shares, completing separation
▲RWE DataClinical Data
Real-world analysis of more than 5,500 users found 9.4 percentage-point difference in Time in Range between higher and lower responders
type 1 diabetessource ↗
▲Topline ReadoutClinical Data
Six-month RCT results: 8.1 percentage points more TIR and 0.6 percentage points lower HbA1c among higher responders
type 1 diabetessource ↗
▲Primary Endpoint MetClinical Data
Smart MDI system met primary endpoint, non-inferior to MDI plus CGM in glycemic outcomes
type 1 diabetessource ↗
Unlock the full MMED catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MMED actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all MMED historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 92%
Small Cap
(rank 665 of 723)
Percentile Rank
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the MMED pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MMED program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
MiniMed™ 780G system type 1 diabetes2026-05-21Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 %Read MoreNew Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G SystemRead More
Scroll for more · summaries link to the source press release
Unlock every MMED trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MMED insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Wills Courtney NelsonOfficer (SVP, Gen. Counsel, Corp. Sec.)Grant/Award 60,730 116,089 held$0.00 07/01/2026
Unlock the full MMED insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 0.4 % 25.70 M 1.32 M
Unlock every fund holding MMED
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MMED
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MMED ownership
Insider and institutional ownership, quarter by quarter.

MMED Short Interest

Shares sold short, counted twice a month.

3.51%
Short % of Float
of tradable shares sold short
9.8M
Shares Sold Short
-52.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
10.2M
Avg Daily Volume
the average used for days to cover
Unlock MMED short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock MMED option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MMED option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MMED options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MMED ranks across every disease it competes in

Competitive Position is a premium feature
See how MMED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MMED News

MMED
Nov 17, 2026
MMEDGeneral
▼ -4.3%today

MiniMed Launches MiniMed Flex™, its Smallest and Most Discrete Insulin Pump, in Europe

MiniMed has launched the MiniMed Flex™, its smallest and most discreet insulin pump, in Europe. This app-controlled system features a screenless design and the SmartGuard™ algorithm, aiming to simplify diabetes management. The pump is compact, holds up to 300 units of insulin, and is designed for users aged two and older. It is gradually rolling out across European markets.

Read more →
MMED
Nov 16, 2026
MMEDFDA Updates
▼ -4.3%today

FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions

MiniMed received FDA clearance for MiniMed Fit™, the first tubeless insulin pump. This device offers up to seven days of wear and a 300-unit insulin capacity. It features SmartGuard technology for automated insulin delivery, aiming to simplify diabetes management. The launch is set for spring 2027, following an early customer experience phase.

Read more →
MMED
Nov 5, 2026
MMEDConferences/Events
▼ -5.9%on this news

MiniMed to Participate in Upcoming Investor Conferences

MiniMed announced that CFO Chad Spooner will participate in several upcoming investor conferences in December 2026. The conferences include the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and Piper Sandler's Annual Healthcare Conference. Live webcasts will be available on the company's Investor Relations website.

Read more →
MMED
Nov 4, 2026
MMEDGeneral
▼ -5.9%on this newsshared move

MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results

MiniMed will report its second quarter financial results for fiscal year 2027 on November 24, 2026. The results will be available via a news release at 3:45 a.m. PST, followed by a webcast at 5:30 a.m. PST. The company has a long-standing commitment to advancing diabetes therapies.

Read more →
MMED
Nov 3, 2026
MMEDGeneral

MiniMed Appoints Dr. David Segal as Chief Medical Officer

MiniMed has appointed Dr. David Segal as Chief Medical Officer, succeeding Dr. Robert Vigersky. Dr. Segal brings over 20 years of experience in diabetes care and digital health. He aims to enhance diabetes management through technology, focusing on proactive and personalized care. Dr. Vigersky will transition to Chief Medical Officer Emeritus ahead of his retirement in 2027.

Read more →
MMED
Oct 15, 2026
MMEDGeneral

MiniMed Announces Board of Directors for its Next Chapter as an Independent Company

MiniMed has announced its new Board of Directors following its separation from Medtronic. The board, led by Kevin E. Lofton, includes experienced professionals from various sectors, focusing on growth and innovation in diabetes technology. CEO Que Dallara emphasized the mission to simplify diabetes management for users. This transition marks a significant step for MiniMed as an independent company.

Read more →
MMED
Oct 15, 2026
MMEDGeneral

MiniMed Completes Separation from Medtronic

MiniMed has successfully completed its separation from Medtronic, marking its first day as an independent entity. CEO Que Dallara expressed gratitude for Medtronic's support and emphasized the new freedom to make impactful decisions for diabetes care. The separation involved an exchange of shares, resulting in Medtronic no longer holding equity in MiniMed.

Read more →
MMED
Oct 5, 2026
MMEDPhases

Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes

A recent six-month randomized trial demonstrated that individuals with type 1 diabetes using the MiniMed Smart MDI system who responded more frequently to alerts had improved glucose outcomes. Specifically, higher responders experienced an average of 8.1 percentage points more Time in Range and a 0.6 percentage point reduction in HbA1c. The findings were presented at the European Association for the Study of Diabetes meeting.

Read more →
MMED
Sep 28, 2026
MMEDGeneral

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

MiniMed has appointed Sheila Denton as General Counsel and Corporate Secretary. Denton, who has over 25 years of experience in the pharmaceutical and biotech sectors, will support the company's growth as it operates as an independent public entity. She succeeds Courtney Nelson Wills and is expected to enhance MiniMed's strategic direction.

Read more →
MMED
Sep 14, 2026
MMEDGeneral

MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement

MiniMed has filed a Form S-4 Registration Statement with the SEC as part of Medtronic's exchange offer for MiniMed shares. Medtronic aims to exchange up to 225 million shares of MiniMed common stock for its ordinary shares. This move marks the final stage of MiniMed's separation from Medtronic, allowing for greater autonomy in operations.

Read more →
MMED
Sep 1, 2026
MMEDGeneral
▲ +10.7%on this news

MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration

MiniMed reported a strong start to fiscal year 2027 with net sales of $843 million, reflecting a 17% increase. The company experienced accelerated U.S. growth of 13% and robust international growth of 18%. MiniMed's innovation pipeline is ahead of schedule, with significant advancements including FDA submissions and new product launches. The company has raised its organic revenue growth guidance for the fiscal year.

Read more →
MMED
Aug 17, 2026
MMEDGeneral

MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor

MiniMed announced that its Flex insulin pump is now shipping with the Instinct sensor. The system allows users to wear the sensor for up to 15 days. Real-world data from the similar 780G system showed users achieved 80 percent time in range. This combination aims to reduce the daily burden of diabetes management.

Read more →
MMED
Jul 22, 2026
MMEDGeneral

MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries

MiniMed has announced that its MiniMed Flex™ insulin pump system is now available to Medicare and Medicare Advantage beneficiaries. This compact, app-controlled device is designed to simplify diabetes management and improve quality of life. The system utilizes SmartGuard™ technology, which automatically adjusts insulin delivery, and has shown positive outcomes in previous studies. The availability of this technology is expected to benefit more individuals living with diabetes.

Read more →
MMED
Jul 20, 2026
MMEDGeneral

MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results

MiniMed (Nasdaq: MMED) announced its upcoming financial results for the first quarter of fiscal year 2027, set to be released on September 1, 2026. The results will be accompanied by a webcast discussion, providing insights into the company's performance. MiniMed continues to innovate in diabetes technology, enhancing the lives of those managing diabetes.

Read more →
MMED
Jun 29, 2026
MMEDGeneral

MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors

MiniMed has appointed David Endicott, CEO of Alcon, and Linnea Burman to its Board of Directors, expanding the board from nine to eleven members. Endicott's experience in scaling healthcare businesses will be valuable as MiniMed continues its journey as an independent company. Burman, from Medtronic, adds further expertise to the board.

Read more →
MMED
Jun 23, 2026
MMEDGeneral

MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

MiniMed launched Instinct sensors in Europe, expanding choice for its automated insulin delivery systems. The company states that glycemic outcomes remain virtually identical when using the new Abbott-made sensors compared to existing options. This integration allows patients to access proven clinical performance with greater flexibility in their diabetes management tools.

Read more →
MMED
Jun 17, 2026
MMEDGeneral

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

MiniMed launched its smallest app-controlled insulin pump, the MiniMed Flex, in the United States. The device pairs with the Simplera Sync sensor to manage diabetes for type 1 and insulin-requiring type 2 patients. Real-world results show an 80% time in range with recommended settings. The system holds 300 units of insulin and is FDA cleared for users aged seven and older.

Read more →
MMED
Jun 3, 2026
MMEDGeneral
▲ +15.9%on this news

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook

MiniMed reported strong financial results for the fourth quarter and full year of fiscal 2026, with net sales reaching $837 million, representing a 16% increase. For the first time, the company's annual net sales surpassed $3 billion, with a 14% overall growth. Positive market response is driven by the adoption of the MiniMed 780G system and successful product launches, including MiniMed Flex and MiniMed Go. Looking ahead, MiniMed projects approximately 10% organic revenue growth for fiscal year 2027, supported by new product offerings and expansion in both U.S. and international markets.

Read more →
MMED
Jun 3, 2026
MMEDGeneral
▲ +15.9%on this news

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

MiniMed has announced an expanded agreement with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems. This collaboration aims to enhance diabetes management by enabling early detection of rising ketones, which can help prevent diabetic ketoacidosis (DKA). The sensors are designed to be the same size as the existing Instinct sensor and will provide users with additional safety features. Regulatory updates and commercialization details are expected in the coming months.

Read more →

About MiniMed Group, Inc.

Northridge, CA 2,800 employees minimed.com
Headquarters18000 DEVONSHIRE ST., NORTHRIDGE, CA, 91325
BIOPHARMAWATCH ELITE
Trade the next MMED catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime